Capromorelin is a ghrelin receptor agonist that is FDA approved for appetite stimulation in dogs. The objective of this study was to evaluate the safety of daily oral administration of capromorelin to cats over a range of doses and for an extended period. Two randomized, controlled studies were conducted: in Study 1, cats (n = 6 per group) received placebo or capromorelin at a dose of 9, 15, 30 or 60 mg/kg once daily for 14 days; and in Study 2, cats received capromorelin at 6 mg/kg (n = 8) or placebo (n = 4) once daily for 91 days. Cats were evaluated using clinical observations and clinical pathology test results for both studies, with the addition of postmortem examination in Study 1 and measurements of growth hormone and insulin-like growth factor 1 in Study 2. Abnormal clinical observations were limited to emesis, hypersalivation, lethargy/depression, head shaking and lip smacking, which occurred more frequently in the capromorelin-treated groups than in the placebo group. There were no clinically relevant differences in clinical pathology test results between the capromorelin and placebo groups in either study.
| INTRODUCTION
Capromorelin is a ghrelin receptor agonist in a class of drugs also known as growth hormone secretagogues (GHSs) that bind to GHS receptors (GHS-Rs) in the hypothalamus, pituitary and other organs. The endogenous ligand for the GHS-R is the peptide hormone ghrelin, which is produced in the stomach in response to fasting, is secreted into the circulation and binds to GHS-Rs in the hypothalamus and pituitary to stimulate appetite and enhance the release of growth hormone (GH) from the pituitary (Cowley et al., 2003; Cummings, Frayo, Marmonier, Aubert, & Chapelot, 2004; Hainerova & Lebl, 2010; Muller et al., 2015; Takaya et al., 2000; Wren et al., 2001 ). In turn, GH promotes the release of insulin-like growth factor 1 (IGF-1) from the liver (Mathews, Hammer, Brinster, & Palmiter, 1988; Mathews, Norstedt, & Palmiter, 1986) . IGF-1 has been shown to enhance differentiation of muscle cells in vitro, and elevated GH and IGF-1 levels are associated with increased overall growth in mice and increased body weight and muscle mass in Beagle dogs (Molon-Noblot et al., 1998; Palmiter, Norstedt, Gelinas, Hammer, & Brinster, 1983; Palmiter et al., 1982; Schmid, Steiner, & Froesch, 1983) . IGF-1 also regulates GH levels through a negative feedback mechanism, thereby preventing overstimulation of GH production (Clemmons, 2004; Yakar et al., 2001 ).
Growth hormone secretagoguess, such as capromorelin, represent a class of drugs that mimic the action of ghrelin to increase appetite and stimulate release of GH. GHSs were originally developed for the treatment of muscle loss and weakness in elderly human patients as well as anorexia and cachexia in human patients with cancer (Carpino et al., 2003; Hersch & Merriam, 2008; Smith, 2005; Temel et al., 2016; White et al., 2009) . Treatment with oral capromorelin was shown to increase IGF-1 levels and total lean body mass in elderly men and women (White et al., 2009 ). In addition, capromorelin has been shown to stimulate appetite, food intake, weight gain and GH and IGF-1 release in dogs (Zollers, Huebner, Armintrout, Rausch-Derra, & Rhodes, 2017; Zollers, Rhodes, & Heinen, 2017; Zollers, Rhodes, & Smith, 2017; Zollers, Wofford, Heinen, Huebner, & Rhodes, 2016) .
Capromorelin is the only Food and Drug Administration (FDA)-approved ghrelin receptor agonist and is currently approved for use in dogs to stimulate appetite. This report describes two randomized, placebo-controlled studies that evaluated the safety of capromorelin in healthy laboratory cats when dosed daily over a large range of doses for 14 or 91 days.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. 
| MATERIALS AND METHODS

| Study 1: 14-day dose-ranging safety study
| Animals
Seventeen intact male and 17 intact female domestic shorthair cats ≥6 months old were bought from Harlan Laboratories (Indianapolis, IN).
Two males and two females were excluded prior to study initiation due to unsatisfactory physical examination results; 15 males and 15 females received study treatments and were included in the analyses. Cats were housed at the Midwest Research Institute (Kansas City, MO) and allowed to acclimate for 10 days prior to study initiation. All cats were provided with IAMS™ ProActive Health™ Adult Original dry cat food ad libitum, except during fasting periods (overnight and prior to sample collection on days 8 and 15), as well as fresh tap water ad libitum.
Animal care and housing were in accordance with the Guide for the 
| Study design
The study design is summarized in Figure 1a . Cats were randomized 1:1:1:1:1 into five treatment groups based on body weight measured 7 days prior to the first dosing, with six cats (three males and three females) per treatment group. Cats were administered capromorelin at doses of 9, 15, 30 or 60 mg/kg or placebo once daily for 14 days approximately 1 hr prior to feeding. Placebo-treated cats received oral capsules containing microcrystalline cellulose alone, whereas capromorelin-treated cats received oral capsules containing the appropriate amount of capromorelin and backfilled with microcrystalline cellulose. Variables of interest were clinical observations for general health, clinical pathology evaluations (including serum chemistry, haematology and urinalysis) and postmortem examination, including histopathology.
| Clinical and laboratory assessments
Cats were observed at least twice daily during acclimation, except on day −6, when they were observed once 6-7 hr after they were given a physical examination. During the dosing period (days 1-14), clinical observations were made prior to dosing, ≤10 min after treatment and 2, 4 and 8 hr after treatment. Body weights were recorded 7 days prior to dosing and at the time of euthanasia.
Haematology and serum chemistry were performed on blood samples collected on day −8 during acclimation and on days 8 and 15 after cats were fasted overnight. Blood samples were collected via jugular vein into BD Vacutainer® (Becton, Dickinson and Company) blood collection tubes containing ethylenediaminetetraacetic acid (EDTA) anticoagulant for haematology or no anticoagulant for serum chemistry. Haematology parameters included white blood cell (WBC) count, WBC differential, red blood cell (RBC) count, haemoglobin, platelet count, haematocrit, mean corpuscular volume, mean corpuscular haemoglobin, mean corpuscular haemoglobin concentration and reticulocytes. Serum chemistry parameters included albumin, globulin, creatine phosphokinase (CPK), alkaline phosphatase, glucose, alanine aminotransferase, blood urea nitrogen (BUN), phosphorus, calcium, potassium, chloride, sodium, total protein, creatinine, total bilirubin, direct bilirubin, amylase and aspartate F I G U R E 1 Study designs for (a) Study 1, the 14-day dose-ranging study, and (b) Study 2, the 91-day study -10 -6
Physical exam
First day of dosing: 9 mg/kg (n = 6) 15 mg/kg (n = 6) 30 mg/kg (n = 6) 60 mg/kg (n = 6) Placebo (n = 6) to those of the control at each study day. The interaction of dose level by study day was statistically significant for CPK, AST, amylase, pH and urine specific gravity.
| Study 2: 91-day safety study
| Animals
Six neutered male and six intact female domestic shorthair cats (age range, 3.0-7.2 years) from the Sinclair Research Center (SRC;
Auxvasse, MO) feline colony were included in the study. Cats were housed at the SRC and allowed to acclimate for 11 days prior to receiving the first study dose. All cats were offered 300 g of Purina®
Cat Chow® for approximately 6 hr each day throughout the acclimation and study drug exposure periods. Water was provided ad libitum. 
| Study design
The study design is summarized in Figure 1b . Cats were randomized 2:1 into two treatment groups, with eight animals (four males and four females) assigned to receive capromorelin at a dose of 6 mg/kg (30 mg/ml solution) orally once per day and four animals (two males and two females) assigned to receive placebo (volume equivalent to a 6 mg/kg dose) orally once per day. The 6 mg/kg capromorelin dose was selected as it was likely to be several fold higher than the anticipated clinical dose, which has yet to be confirmed in cats. Cats were administered capromorelin or placebo via syringe on days 1 through 91. Initial dose was calculated using body weight measured on the day prior to first dosing, and dose was adjusted following body weight measurement on days 14, 30, 59 and 75.
Cats were offered food 1 hr after dosing, and food was removed after 6 hr. On days −11 through 90, food consumption was determined daily for all cats. During the acclimation period, baseline food consumption values were calculated using the average of days −3 through −1 for all animals. Variables of interest were clinical observations and physical examinations for general health, clinical pathology tests (including serum chemistry, haematology and urinalysis) and serum levels of GH and IGF-1.
| Clinical and laboratory assessments
General health observations were performed at least once daily throughout the study. Physical examinations were performed at the beginning of the acclimation period (day −11) and on days 1, 30, 59
and 91. Body weights were measured on days −11, −1, 1, 14, 30, 59, 75 and 91 prior to dose administration and feeding. 
| Statistical analysis
Statistical analyses were performed using SAS version 9. Descriptive statistics (number of subjects, mean, standard deviation, standard error of the mean and median, minimum and maximum values) were presented for each time point collected by treatment group. For continuous haematology, serum chemistry and urinalysis measurements, descriptive statistics were presented for each day by treatment group. For values collected at >1 time point, repeatedmeasures analysis of variance was used to test for differences between treatment groups. SAS/STAT Proc MIXED was implemented using a model containing terms for treatment group, study day and the interaction of treatment-by-study day, with the baseline value included in the model as a covariate. Possible differences between treatment groups on each study day were determined from this model.
The covariance structure (variance components, compound symmetry, heterogeneous compound symmetry, first-order autoregressive or heterogeneous autoregressive structure) that provided the smallest Akaike information criterion value was used.
Analysis of variance was used to test for differences between treatment groups for parameters with one value per subject. SAS/ STAT Proc MIXED was implemented using a model containing a term for treatment group, with the baseline value included in the model as a covariate, if possible. For GH and IGF-1, differences within treatment groups were assessed by the Wilcoxon rank sum test. Table 1 ). The incidence of emesis was comparable between the placebo group and the 9 mg/kg and 15 mg/kg groups, but higher in the 30 mg/kg and 60 mg/kg groups; emesis generally occurred within 2 hr after dosing. Hypersalivation was only observed in the 30 mg/kg and 60 mg/kg groups; hypersalivation primarily occurred during and immediately after dosing. Lethargy/depression, defined as reluctance to stand, was only observed for cats in the 30 mg/ kg group (two cats on day 1) and the 60 mg/kg group (three cats on day 1 and one cat on day 2); lethargy/depression was most pronounced within 6 hr of dosing.
| Haematology, serum chemistry and urinalysis
Haematology measurements were generally comparable between all capromorelin and placebo groups (Table S1 ). Reference ranges were not supplied by the laboratory for Study 1, so ranges from the Merck Veterinary Manual (MVM) are provided here (Aiello, 2016) .
However, the Study 2 ranges may be more relevant as they represent ranges in healthy laboratory cats. Occasional values outside the reference ranges for haematology parameters were reported in cats in all groups, including the placebo group, both at baseline and throughout the study. Some statistically significant differences in haematology measurements between cats that received capromorelin and those that received placebo were observed. Additionally, the overall capromorelin treatment effect was statistically significant for elevated platelet count. However, most changes in haematology measurements remained within the corresponding reference ranges, and these changes were not considered clinically relevant. There was no significant treatment-by-study day interaction for any haematology measure. Some results were outside of the MVM reference ranges across all groups. For per cent lymphocytes and per cent eosinophils, all groups had mean values above the reference ranges at most timepoints; however, there was no treatment effect and these differences were likely due to factors unique to this population.
Serum chemistry measurements were generally comparable between all groups (Table S2 ). Some statistically significant differences in serum chemistry measurements were observed between cats that received capromorelin and those that received placebo; however, most changes remained within the corresponding reference ranges and were not considered clinically relevant. Based on the MVM ref-
erence ranges, results for most cats at most timepoints were above the listed ranges for ALP, CPK and phosphorus. The "elevated" ALP
and phosphorus values were consistent with ranges reported for 4-to 6-month-old kittens (37-333 U/L for ALP and 6.0-10.4 mg/dl for phosphorus) (von Dehn, 2014 Urinalysis results were generally comparable between all capromorelin and placebo groups. The overall capromorelin treatment effect was statistically significant for urine specific gravity, and the treatment-by-study day interaction was statistically significant for urine specific gravity and urine pH (Table S3 ). Urine specific gravity was statistically significantly higher in all capromorelin-treated groups than in the placebo group on day 8, but the difference was statistically significant only for the 60 mg/kg group on day 15. Urine pH was statistically significantly lower in all capromorelin-treated groups than in the placebo group on day 8; however, only the 15 mg/kg group had a statistically significantly different urine pH compared with the placebo group (7.42 vs 6.58, respectively) on day 15. All cats had negative bilirubin and ketone tests throughout the study, with the exception of two males in the 15 mg/kg group and one male in the 60 mg/kg group that had trace ketone levels (5 mg/dl) on day 15. Some cats in all groups had transient elevations in pH and protein throughout the study, including pretreatment. Additionally, some cats in all groups had sporadic positive tests for occult blood, RBCs, WBCs, epithelial cells, bacteria and crystals throughout the study, including pretreatment.
Glycosuria was reported in one male on day 8 and one male on days 8 and 15 in the 30 mg/kg group, which corresponded with elevated serum glucose in the second cat on both days. Glycosuria was also reported in two females on day 8 and one male on days 8 and 15 in the 60 mg/kg group, which corresponded with elevated serum glucose in the male on day 15 only.
| Necropsy and histology
The overall capromorelin treatment effect was statistically significant for absolute weight and relative weight of the liver (absolute, p = .048; relative, p = .036) and right adrenal gland (absolute, p = .064; relative, T A B L E 1 Abnormal clinical observations in cats treated with placebo or capromorelin 9, 15, 30 or 60 mg/kg once daily for 14 days in Study 1 p = .095). For both the liver and right adrenal gland, the mean organ weight and mean organ weight relative to body weight were greater in each capromorelin-treated group than in the placebo group. Gross pathology findings were limited to one cat with a pale thymus (normal on histopathology) and one cat with a cryptorchid testis (degenerative on histopathology) in the placebo group and one cat with diffusely mottled lungs (congestion on histopathology) and an enlarged urinary bladder (normal on histopathology) in the 60 mg/kg capromorelin group. Histopathology findings were infrequent overall, generally of minimal or mild severity and similarly distributed between the capromorelin and placebo groups (summarized in Table S4 ).
| Study 2: 91-day safety study
| Clinical observations
All animals maintained or increased body weight during the study.
Both the overall capromorelin treatment effect and the treatmentby-study day interaction for body weight were statistically significant (p < .0001). The capromorelin-treated group had statistically significant increases in mean body weight from day 1 at day 14 (p = .003), day 30 (p = .001), day 59 (p < .0001), day 75 (p < .0001) and day 91 (p < .0001) compared with the placebo-treated group, whose mean body weight was stable (Figure 3a) . The change from baseline food consumption was larger for capromorelin-treated cats than for placebo-treated cats; however, neither the overall treatment effect nor the analysis of the rate of change was statistically significant (p = .091 and p = .057, respectively; Figure 3b ).
Abnormal clinical observations were limited to emesis, hypersalivation, head shaking and lip smacking, all of which occurred immediately after dosing and generally resolved within 5 min. Cats that received capromorelin 6 mg/kg experienced a greater frequency of abnormal clinical observations compared with those that received placebo (Table 2 ). In particular, six cats (75%) in the capromorelin group experienced hypersalivation on a range of 1-89 days, whereas one cat (25%) in the placebo group experienced hypersalivation on 1 day.
Similarly, eight cats (100%) in the capromorelin group displayed lip smacking on a range of 4-82 days, whereas three cats (75%) in the placebo group displayed lip smacking on a range of 1-2 days.
| Haematology, serum chemistry and urinalysis
Haematology measurements were generally comparable between the placebo and capromorelin groups (Table S5) Serum chemistry measurements were also generally comparable between the groups (Table S6) F I G U R E 3 Mean (a) body weight (±SD) and (b) food consumption (+SD) over time in cats treated with capromorelin 6 mg/kg or placebo in Study 2. *Change from baseline in body weight was significantly different (p < .05) in the capromorelin group compared with that in the placebo group Statistically significant treatment-by-study day interactions were observed for sodium (p = .042), creatinine (p = .025), albumin/globulin ratio (p = .015) and cholesterol (p = .020).
There were no statistically significant overall treatment effects or treatment-by-study day interactions observed for urine pH or urine specific gravity throughout the study (Table S7) , and total urine protein measurements were consistent throughout. Urinalysis results for all cats were negative for WBCs, casts and ketones throughout the study, with the exception of one cat in the capromorelin group that had trace ketones on day 91. Most cats in both groups had few to moderate numbers of crystals throughout the study, including pretreatment.
Some cats in both groups were transiently positive for low numbers of RBCs (1-3 cells per high-power field), rare squamous epithelial cells, low to moderate levels of bacteria and trace or low levels of bilirubin and blood during the study, including pretreatment. Trace glycosuria was observed in one capromorelin-treated cat on days 30 and 91 and in one placebo-treated cat on day 30.
| Serum GH and IGF-1
Cats treated with capromorelin had statistically significant increases in mean serum GH from 0 hr to 8 hr on day 1 (p = .016), day 30 (p = .039) and day 91 (p = .023); the greatest capromorelin-stimulated increase in GH was observed on day 1 (Figure 4a) . No statistically significant differences in GH levels were found in the placebo group between the 0-hr and 8-hr time points on any day. When only 0-hr results for serum GH were analysed for the overall study, neither overall treatment effect nor treatment-by-study day interaction were statistically significant. Cats in the capromorelin group had significantly higher increases in mean GH from 0 hr to 8 hr on day 1 (p = .031) and day 30 (p = .007) compared with those in the placebo group.
Cats treated with capromorelin had statistically significant increases in mean serum IGF-1 from 0 hr to 8 hr on day 1 (p = .008) and day 91 (p = .016; Figure 4b ). No statistically significant differences in IGF-1 levels were found in the placebo group between the 0-hr and 8-hr time points on any day. Cats in the capromorelin group, but not in the placebo group, had significantly higher mean serum IGF-1 levels at 0 hr on days 30, 59 and 91 (p = .008 for all) than at 0 hr on day 1. When only 0-hr results were analysed for the overall study, the overall treatment-by-study day interaction was statistically significant (p = .022). However, the differences in mean IGF-1 levels at 0 hr F I G U R E 4 Mean serum (a) GH and (b) IGF-1 levels predosing (0 hr) and 8 hr after dosing in cats treated with capromorelin 6 mg/kg or placebo in Study 2. GH, growth hormone; IGF-1, insulin-like growth factor 1. *Mean value was significantly greater at 8 hr (p < .05) than at 0 hr on the same study day within the treatment group. † Change from 0 hr to 8 hr was significantly greater (p < .05) in the capromorelin group compared with that in the placebo group on the same study day. ‡ Mean value was significantly greater at 0 hr on a given study day (p < .05) than at 0 hr on day 1 within the treatment group between the placebo and capromorelin groups on any study day were not statistically significant.
| DISCUSSION
The results of these studies provided preliminary safety information on the daily administration of capromorelin over a range of doses and for an extended period in cats. Abnormal clinical observations were mild and included emesis, hypersalivation, lethargy/depression, head shaking and lip smacking. In Study 1, in which capromorelin was administered in an oral capsule formulation, abnormal clinical observations generally occurred immediately upon dosing to <6 hr after dosing and were primarily observed in cats that received 30 or 60 mg/kg of capromorelin. In Study 2, in which capromorelin was administered in a liquid formulation, abnormal clinical observations occurred immediately upon dosing and generally resolved within 5 min. Although there were some statistically significant differences in mean haematology and serum chemistry parameters between cats in treatment groups receiving capromorelin and those receiving placebo in both studies, most changes remained within the corresponding reference ranges and were not considered clinically significant; urinalysis results were comparable between the treatment groups.
Sporadic increases in serum and urine glucose were observed in capromorelin-treated cats during both studies. Based on the sporadic incidences of elevated glucose in Study 1, it was unclear whether the elevated glucose results were secondary to stress or represented persistent hyperglycaemia (Feldhahn, Rand, & Kinnaird, 1999; Kojima et al., 2000; Rand, Kinnaird, Baglioni, Blackshaw, & Priest, 2002) . Increases in GH and IGF-1 are expected with capromorelin treatment (Hersch & Merriam, 2008; Zollers, Rhodes, & Smith, 2017) .
Chronically elevated GH and IGF-1 levels in cats are often a sign of hypersomatotropism (acromegaly) (Berg et al., 2007; Peterson et al., 1990) ; however, few studies have evaluated GH and IGF-1 levels in a large number of healthy cats (Tschour et al., 2012) . Based on the overall results in the placebo-treated cats in Study 2, the observed ranges were 2.10-7.97 ng/ml for GH and 120-956 ng/ml for IGF-1 (reference ranges were not available from the laboratory). In capromorelintreated cats, GH was markedly increased after the first dose, as expected. Following treatment, statistically significant differences in GH levels between the capromorelin and placebo groups were observed on day 1 and to a much lesser extent on day 30. Statistically significant increases in IGF-1 8 hr after dosing were observed only on days 1 and 91 in the capromorelin group; however, statistically significant increases in IGF-1 were seen at 0 hr on days 30, 59 and 91 compared with 0 hr at day 1, indicative of chronic, consistent increases in IGF-1 levels. Presumably, negative feedback from these sustained elevated levels of IGF-1 attenuated capromorelin stimulation of GH release over time.
This situation is markedly different from that of cats with hypersomatotropism, in which the pituitary tumour persistently secretes GH, resulting in chronically elevated serum GH in addition to elevated IGF-1 levels (Berg et al., 2007; Peterson et al., 1990 ). An IGF-1 measurement >1000 ng/ml is generally used to aid in the diagnosis of hypersomatotropism (Niessen et al., 2007 (Niessen et al., , 2015 Tschour et al., 2012) .
Some capromorelin-treated cats in Study 2 had IGF-1 levels >1000 ng/ ml at some time points, with a maximum value of 1498 ng/ml recorded in this study (predosing on day 30). Interestingly, the maximum IGF-1 value observed in a placebo-treated cat (956 ng/ml) approached the 1000-ng/ml threshold. In hypersomatotropism, a tumour produces excess GH, which is resistant to negative feedback from IGF-1. Thus, the significance of constitutively increased IGF-1 in the context of downregulated GH is unknown. One limitation of these studies is the lack of capromorelin pharmacokinetics in cats. However, biologically active levels of capromorelin were clearly achieved because the observed capromorelin-stimulated increases in serum GH and IGF-1 demonstrated the expected physiological activity of capromorelin.
These initial safety studies were performed in healthy laboratory cats under controlled conditions of food intake. Although it is encouraging that no serious adverse events were observed, clinical studies in client-owned cats will be required to demonstrate safety in the target population.
Capromorelin is FDA approved for appetite stimulation in dogs and has been shown to result in increased food consumption and body weight in laboratory Beagle dogs after as few as 4 days of treatment with capromorelin 3 mg/kg oral solution for dogs (Zollers, Rhodes, & Heinen, 2017) . However, in Study 1, there was no statistically significant treatment effect of capromorelin on body weight, although the cats were ≥6 months of age at the start of the study and all cats gained weight from day −7 to day 15. Given the small group size, the study was likely underpowered to detect treatmentrelated differences in weight gain in growing kittens. In Study 2, treatment with capromorelin resulted in statistically increased body weight over 91 days. Although mean food consumption was greater
